Related Experiment Videos
Treatment with the NO-synthase inhibitor, methylene blue, moderates the decrease in serum leptin concentration in
M Haluzik1, J Nedvídková, J Skrha
13 Medical Department, 1 Faculty of Medicine, Prague, Czech Republic. MHALU@LF1.CUNI.CZ
Endocrine Research
|June 26, 1999
Summary
Methylene blue, a nitric oxide synthase inhibitor, partially reversed diabetes-induced drops in body weight and serum leptin in rats. This suggests insulin deficiency, not just diabetes, drives leptin reduction.
Area of Science:
- Biomedical Science
- Endocrinology
- Metabolic Disorders
Background:
- Serum leptin levels decrease in streptozotocin-induced diabetes in rats.
- Nitric oxide (NO)-synthase inhibitors can partially mitigate diabetes development.
Purpose of the Study:
- To investigate the effect of the NO-synthase inhibitor, methylene blue, on serum leptin concentration and diabetes progression.
- To determine if methylene blue influences diabetes development and associated metabolic changes.
Main Methods:
- Rats were divided into control, diabetic (streptozotocin), methylene blue treated, and diabetic + methylene blue treated groups.
- Measurements included body weight, blood glucose, glycated hemoglobin, and serum leptin concentration over six weeks.
Main Results:
- Diabetes significantly increased blood glucose and glycated hemoglobin, which was partially attenuated by methylene blue.
- Diabetic rats showed decreased body weight and serum leptin; methylene blue treatment partially inhibited these decreases.
- Methylene blue significantly inhibited the drop in serum leptin in diabetic rats.
Conclusions:
- The reduction in serum leptin in diabetic rats is likely primarily due to streptozotocin-induced insulin deficiency.
- NO-synthase inhibition with methylene blue partially ameliorates diabetes development and its effect on leptin levels.